CelGen

Our Whole-Body Microcurrent Technology Helps Diabetics Avoid Amputation.

This therapy stimulates the muscles with microfribulations that improve circulation and use up excess sugars trapped in the extremities that lead to neuropathy, open sores, and bruises.

In its brief pilot test, CelGen successfully prevented 5 out of 5 amputations scheduled within 1 week of the trial. It also reduced critically high blood sugar levels by 140 points in just 20 minutes, as measured by a blood sugar monitor. The device rapidly reduces blood sugar levels, manages pain from neuropathy, and enhances micro-circulation.

What Happens During a Session?

The device consists of a platform and an applicator bulb. The user holds the bulb to the affected area and places their feet on the platform. It feels like a buzzing and tingling electric massage on the feet and hands. Users can reduce the intensity of the treatment if necessary by lifting one foot from the platform.

By holding the bulb with their feet on the platform, the user completes a biological circuit that allows the full frequency spectrum of microcurrent electricity to safely pass through their body. This energy causes the muscles to tense and release rapidly. The body uses the glucose already in the blood and local tissue to fuel the muscle activity, immediately and drastically reducing sugar levels.

With continued use, glucose trapped in the extremities is used up in exercise and the surge in circulation assists in the normal healing of chronic wounds, sores, bruises and managing pain from various forms of neuropathy.

About the Market

We are in the Neuropathic Pain market. In the United States, the market was worth $1.86B as of 2015. Our niche is in Diabetic Neuropathy, which accounts for over 46% of the global market and analysts forecast will grow at a CAGR of 8% through 2018. According to the World Health Organization (WHO), approximately 350 million people worldwide suffer from diabetes, with 1.4 million Americans diagnosed every year.

About 60% of all non-traumatic lower-limb amputations in the United States occur in people diagnosed with diabetes. Of the diabetics who have such an amputation, up to 55% will also require amputation of their remaining leg within 2 to 3 years.

There are treatments and medications that manage neuropathic pain due to diabetes, but to date there is no treatment that mitigates or cures neuropathy itself.

Learn More About CelGen